I just got an email from Hancock Jaffe Laboratories. " First U.S. Patent Allowed on Hancock Jaffe VenoValve  Company Receives Notice of Allowance from U.S. Patent and Trademark Office "
t
Kind of a boring stock right now, but it should be a faster pace to approval than a drug company. and I believe the results will be pretty clear unlike a lot of drugs approved thats barely better than nothing and questionable on if or how long it will be on the market.
D
The patent is good news but keep in mind it's only one of several patents applied for and the product is still in the clinical stages.
A
Who is giving this $25 price target?
R
just bought some more... all I can say is I hope they use the money wisely!
Stocks on sale. Low 8’s should be money in the bank
t
premarket
D
Approximately 2.4 million people in the U.S. suffer from CVI due to reflux in the deep venous system. Estimates indicate that direct medical costs from CVI in the U.S. exceed $38 Billion a year. There are currently no FDA approved devices, or effective treatments for deep venous CVI.
L
just bought. a good buy at 7.15
J
Update: 9,000 unrealized gain from this decision. And
D
Is there any updates on this stock?
S
No bump this time, but we are headed in the right direction. US pivot trial will begin and we should be commercialize late 2022, if all goes well.
R
finally hit the news
Bullish
L
If you are here to short term trade, leave. This is going to be a winner long term. So if you have no patience to sit for 6-12 months more, you need to trade bitcoin and go to a casino
S
Could someone clarify for me. Isn't this FDA meeting just to formalize a trial? Maybe FDA fast tracks this but I don't think they'll approve prior to a formal trial, correct?
D
Kinda of getting tired of holding this. I bet on it instead of avinger, and kind is disappointed a bit I didn’t go with avinger instead. Still holding though
R
What’s going on? Any news?
L
Either by end of day or AM, the news on this positive FDA meeting will make this soar well above $10....
Â
Company Receives Notice of Allowance from U.S. Patent and Trademark Office "